Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial

Respiratory Medicine

Volumn 108, Issue 12, 2014, Pages 1752-1760

  Maleki Yazdi, M Reza ^a   Kaelin, Thomas ^b   Richard, Nathalie ^c   Zvarich, Michael ^c   Church, Alison ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Lowcountry Lung and Critical Care PA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Long acting bronchodilator; Umeclidinium; Vilanterol

Indexed keywords

SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; QUINUCLIDINE DERIVATIVE; SCOPOLAMINE DERIVATIVE; UMECLIDINIUM; VILANTEROL;

ADULT; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; AGED; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

AGED; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84925396337     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.10.002     Document Type: Article

References (22)

1. Celli BR, MacNee W. ATS/ERS Task Force, standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
2. GOLD, Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, http://www.goldcopd.org/ [accessed March 2014].
3. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006; 15: 32-6.
4. Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2011, http://www.goldcopd.org/uploads/users/files/GOLD-Report-2011-Feb21.pdf [accessed March 2014].
5. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-8.
6. Tashkin DP, Varghese ST. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tio-tropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2011; 24: 147-52.
7. Maltais F, Beck E, Webster D, et al. Four weeks oncedaily treatment with tiotropium+olodaterol (BI1744) fixed dose combination compared with tiotropium in COPD patients (5557). Eur Respir J 2010; 38(Suppl. 5): 1014s.
8. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014 [Epub ahead of print].
9. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013; 185: 393-9.
10. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107: 1538-46.
11. Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43: 72-81.
12. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2: 472-86.
13. Boehringer-Ingelheim, Tiotropium prescribing information, http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf [accessed March 2014].
14. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19: 227-46.
15. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tio-tropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6: 17-25.
16. Han M-L, Brooks J, Church A, Kalberg C. Bronchodilator response to the long-acting bronchodilator combination of umeclidinium/vilanterol across subgroups of patients with COPD. In: American Thoracic Society e 110th International Conference, Vol. 189; 2014. A3762.
17. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-94.
18. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert. Opin Pharmacother 2013; 14: 775-81.
19. Salpeter SR Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21: 405-14.
20. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-50.
21. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in copd-related hospitalizations in the united states, 1979 to 2001. Chest 2005; 128: 2005-11.
22. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-107.